In addition, high expression of AQP3 in triple-negative breast cancer was associated with a worse prognosis, while in HER2-positive breast cancer, AQP3 was in the group of genes predicting worse relapse-free survival after neoadjuvant chemotherapy plus either trastuzumab and/or lapatinib [41]. Here, ERBB2 is linked to breast cancer.